GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Hold” from Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have earned an average rating of “Hold” from the fifteen analysts that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $3.8125.

Several brokerages have recently issued reports on GDRX. The Goldman Sachs Group reiterated a “neutral” rating and set a $3.50 price target on shares of GoodRx in a research report on Friday, May 8th. Wells Fargo & Company lowered their price target on GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. Citigroup lifted their price target on GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. Weiss Ratings cut GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 20th. Finally, TD Cowen lifted their price target on GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, May 11th.

GoodRx Stock Up 1.8%

Shares of GoodRx stock opened at $2.85 on Thursday. The business’s fifty day moving average price is $2.63 and its two-hundred day moving average price is $2.48. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47. The company has a market capitalization of $976.34 million, a P/E ratio of 47.51, a PEG ratio of 1.30 and a beta of 1.61. GoodRx has a 1-year low of $1.77 and a 1-year high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. GoodRx had a return on equity of 7.90% and a net margin of 2.61%.The firm had revenue of $194.01 million for the quarter, compared to the consensus estimate of $185.40 million. During the same quarter in the previous year, the business earned $0.09 EPS. The firm’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, research analysts forecast that GoodRx will post 0.17 EPS for the current year.

Hedge Funds Weigh In On GoodRx

Several hedge funds have recently modified their holdings of GDRX. Essential Partners LLC grew its holdings in shares of GoodRx by 375.4% in the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock worth $28,000 after acquiring an additional 11,295 shares during the last quarter. Amundi acquired a new position in shares of GoodRx in the 1st quarter worth $37,000. Renaissance Technologies LLC grew its holdings in shares of GoodRx by 1.5% in the 1st quarter. Renaissance Technologies LLC now owns 3,259,738 shares of the company’s stock worth $6,389,000 after acquiring an additional 48,800 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in shares of GoodRx in the 1st quarter worth $55,000. Finally, DGS Capital Management LLC acquired a new position in shares of GoodRx in the 1st quarter worth $48,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.